Novartis reported CHF3.75B in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbvie ABBV:US $ 4142M 121M
Alcon AG ALC:SW 922.43M 49.57M
Amgen AMGN:US $ 1510M 51M
AstraZeneca AZN:LN 1904M 375M
Bayer BAYN:GR € 5680M 504M
Biogen BIIB:US $ 484M 269.9M
Bristol Myers Squibb BMY:US $ 2677M 206M
Eli Lilly And LLY:US $ 1430.5M 641.6M
Fresenius FRE:GR € 7340M 178M
Fresenius Medical Care FME:GR € 3411M 120.73M
Galapagos GLPG:NA 2.63M 279K
Gilead Sciences GILD:US $ 1442M 18M
GlaxoSmithKline GSK:LN 2136M 1509M
Hikma Pharmaceutical HIK:LN 590M 62M
Johnson & Johnson JNJ:US $ 7919M 321M
Lonza Group LONN:SW 1.79B 14M
Merck MRK:GR € 2109M 122M
Merk MRK:US $ 3698M 1636M
Novartis NVS:US $ 3749M 6M
Novartis NOVN:VX SF 3749M 6M
Orion ORNBV:FH 110.2M 4.1M
Pfizer PFE:US $ 8671M 1339M
Philips PHIA:NA € 2445M 38M
Recordati REC:IM 152.4M 36.92M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M